Cargando…

The Optimal Strategy of Dual Antiplatelet Therapy after Percutaneous Coronary Intervention with Drug-Eluting Stent

Objective: To test the optimal strategy of dual antiplatelet therapy (DAPT) after implantation of drug-eluting stents (DESs) according to specific DAPT time and subsequent monotherapy. Methods: We searched the Cochrane Central Register of Controlled Trials (CENTRAL), Medline, Embase, and Web of Scie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hu, Mengjin, Gao, Xiaojin, Yang, Jingang, Yang, Yuejin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Systematic Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9370028/ https://www.ncbi.nlm.nih.gov/pubmed/35956082 http://dx.doi.org/10.3390/jcm11154465

Ejemplares similares

Comparison of Six Different Percutaneous Coronary Intervention Guidance Modalities
por: Hu, Mengjin, et al.
Publicado: (2022)

Thirty-Days versus Longer Duration of Dual Antiplatelet Treatment after Percutaneous Coronary Interventions with Newer Drug-Eluting Stents: A Systematic Review and Meta-Analysis
por: Tsigkas, Grigorios, et al.
Publicado: (2023)

Impact of Anemia and Dual Antiplatelet Therapy on Mortality in Patients Undergoing Percutaneous Coronary Intervention with Drug-Eluting Stents
por: Wang, Huili, et al.
Publicado: (2015)

Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials
por: Navarese, Eliano Pio, et al.
Publicado: (2015)

Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials
Publicado: (2016)

Optimizing the Duration of Dual Antiplatelet Therapy After Implantation of Drug-eluting Coronary Stents
por: Shen, Ying, et al.
Publicado: (2015)

Duration of dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stent: systematic review and network meta-analysis
por: Yin, Shang-He-Lin, et al.
Publicado: (2019)

Dual Antiplatelet Therapy After Percutaneous Coronary Intervention and Drug-Eluting Stents: A Systematic Review and Network Meta-Analysis
por: Khan, Safi U., et al.
Publicado: (2020)

Efficacy and safety of dual antiplatelet therapy after percutaneous coronary drug-eluting stenting: A network meta-analysis
por: Luo, Lin, et al.
Publicado: (2022)

Comparison of 6-Month and Prolonged Dual Antiplatelet Therapy after Percutaneous Coronary Intervention with Biodegradable Polymer Everolimus-Eluting Stent
por: Yoon, Yong-Hoon, et al.
Publicado: (2022)

Duration of dual antiplatelet therapy in patients with acute coronary syndrome undergoing drug-eluting stent implantation: A meta-analysis
por: Geng, Xue, et al.
Publicado: (2020)

Benefits and Harms of Extending the Duration of Dual Antiplatelet Therapy after Percutaneous Coronary Intervention with Drug-Eluting Stents: A Meta-Analysis
por: Kwok, Chun Shing, et al.
Publicado: (2014)

One-Month Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention With Zotarolimus-Eluting Stents in High-Bleeding-Risk Patients
por: Kandzari, David E., et al.
Publicado: (2020)

Benefit and Risk of Prolonged Dual Antiplatelet Therapy After Percutaneous Coronary Intervention With Drug-Eluting Stents in Patients With Elevated Lipoprotein(a) Concentrations
por: Cui, Kongyong, et al.
Publicado: (2021)

Optimal Duration of Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents: Shorter or Longer?
por: Chang, Mineok, et al.
Publicado: (2014)

Dual antiplatelet therapy and drug eluting stents: a marriage of convenience
por: Benezet-Mazuecos, Juan, et al.
Publicado: (2007)

Beta-Blocker Use after Discharge in Patients with Acute Myocardial Infarction in the Contemporary Reperfusion Era
por: Hu, Mengjin, et al.
Publicado: (2022)

Is the Duration of Dual Antiplatelet Therapy after Implantation of Drug-Eluting Stents the Longer the Better?
por: Huang, Qing-Yu, et al.
Publicado: (2015)

Duration of Dual Antiplatelet Therapy and Late Stent Thrombosis Following Percutaneous Coronary Intervention with Second-Generation Drug-Eluting Stents: A Simple Meta-Analysis of Randomized Controlled Trials
por: Lin, Bei-you, et al.
Publicado: (2019)

Clinical outcomes of prolonged dual antiplatelet therapy after coronary drug-eluting stent implantation in dialysis patients
por: Park, Seokwoo, et al.
Publicado: (2020)

Optimal Strategy for Antiplatelet Therapy After Coronary Drug-Eluting Stent Implantation in High-Risk “TWILIGHT-like” Patients With Diabetes Mellitus
por: Wang, Hao-Yu, et al.
Publicado: (2020)

Clinical results of everolimus-eluting stents and sirolimus-eluting stents in patients undergoing percutaneous coronary intervention
por: Jafaripour, Iraj, et al.
Publicado: (2023)

Optimal duration of dual antiplatelet therapy after drug eluting stent implantation: a network meta-analysis
por: Gajulapalli, Rama Dilip, et al.
Publicado: (2017)

Stent thrombosis associated with drug eluting stents on addition of cilostazol to the standard dual antiplatelet therapy following percutaneous coronary intervention: a systematic review and meta-analysis of published randomized controlled trials
por: Huang, Feng
Publicado: (2018)

Risk Factors for Coronary Drug-Eluting Stent Thrombosis: Influence of Procedural, Patient, Lesion, and Stent Related Factors and Dual Antiplatelet Therapy
por: Sudhir, Krishnankutty, et al.
Publicado: (2013)

New predictors of in-stent restenosis in patients with diabetes mellitus undergoing percutaneous coronary intervention with drug-eluting stent
por: Wang, Jian-Long, et al.
Publicado: (2018)

Study protocol for a randomised controlled trial: harmonising optimal strategy for treatment of coronary artery stenosis — coronary intervention with next-generation drug-eluting stent platforms and abbreviated dual antiplatelet therapy (HOST-IDEA) trial
por: Kim, Chi-Hoon, et al.
Publicado: (2017)

Coronary pseudoaneurysm 1 week after complex percutaneous coronary intervention with drug‐eluting stent
por: Namazi, Mohammad Hasan, et al.
Publicado: (2020)

One-Year Outcome of Everolimus-Eluting Stents Versus Biolimus-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention
por: Alidoosti, Mohammad, et al.
Publicado: (2016)

Percutaneous coronary intervention in patients with cancer using bare metal stents compared to drug-eluting stents
por: Ahmed, Talha, et al.
Publicado: (2022)

Optimal duration of dual antiplatelet therapy following percutaneous coronary intervention: protocol for an umbrella review
por: Elliott, Jesse, et al.
Publicado: (2017)

Risk of non-cardiac surgery after percutaneous coronary intervention with drug-eluting stents
por: Park, Sun-Kyung, et al.
Publicado: (2017)

Newer-Generation Drug-Eluting Stents in Patients Undergoing Complex Percutaneous Coronary Intervention
por: Otsuka, Kenichiro
Publicado: (2021)

Use of Mendelian randomization to evaluate the effect of atrial fibrillation on cardiovascular diseases and cardiac death
por: Hu, Mengjin, et al.
Publicado: (2022)

Everolimus-Eluting versus Paclitaxel-Eluting Stents in Percutaneous Coronary Intervention: Meta-Analysis of Randomized Trials
por: Alazzoni, Ashraf, et al.
Publicado: (2012)

Perioperative management of antiplatelet therapy in patients with drug-eluting stents
por: Dimitrova, G, et al.
Publicado: (2012)

Shortened dual antiplatelet therapy in contemporary percutaneous coronary intervention era
por: Han, Jennie, et al.
Publicado: (2021)

Stent thrombosis and optimal duration of dual antiplatelet therapy after coronary stenting in contemporary practice
por: Cho, Min Soo, et al.
Publicado: (2017)

Stent-Related Adverse Events as Related to Dual Antiplatelet Therapy in First- vs Second-Generation Drug-Eluting Stents
por: Yoshikawa, Yusuke, et al.
Publicado: (2021)

Everolimus-eluting stent platforms in percutaneous coronary intervention: comparative effectiveness and outcomes
por: Panoulas, Vasileios F, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ravcuf33gsemavo6o115nu1c97